JP2016536369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536369A5 JP2016536369A5 JP2016552455A JP2016552455A JP2016536369A5 JP 2016536369 A5 JP2016536369 A5 JP 2016536369A5 JP 2016552455 A JP2016552455 A JP 2016552455A JP 2016552455 A JP2016552455 A JP 2016552455A JP 2016536369 A5 JP2016536369 A5 JP 2016536369A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- composition according
- binding protein
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900246P | 2013-11-05 | 2013-11-05 | |
| US61/900,246 | 2013-11-05 | ||
| US201462016620P | 2014-06-24 | 2014-06-24 | |
| US62/016,620 | 2014-06-24 | ||
| PCT/US2014/063951 WO2015069668A1 (en) | 2013-11-05 | 2014-11-04 | Method of treating conditions of the eye with an anti-vegf darpin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106978A Division JP2020169191A (ja) | 2013-11-05 | 2020-06-22 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016536369A JP2016536369A (ja) | 2016-11-24 |
| JP2016536369A5 true JP2016536369A5 (OSRAM) | 2018-02-22 |
Family
ID=51947485
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552455A Pending JP2016536369A (ja) | 2013-11-05 | 2014-11-04 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
| JP2020106978A Pending JP2020169191A (ja) | 2013-11-05 | 2020-06-22 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
| JP2022076645A Pending JP2022107628A (ja) | 2013-11-05 | 2022-05-06 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106978A Pending JP2020169191A (ja) | 2013-11-05 | 2020-06-22 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
| JP2022076645A Pending JP2022107628A (ja) | 2013-11-05 | 2022-05-06 | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20150126458A1 (OSRAM) |
| EP (2) | EP3628324A1 (OSRAM) |
| JP (3) | JP2016536369A (OSRAM) |
| KR (1) | KR20160070164A (OSRAM) |
| CN (1) | CN105960247A (OSRAM) |
| AU (2) | AU2014346921A1 (OSRAM) |
| CA (1) | CA2927012A1 (OSRAM) |
| DK (1) | DK3065761T3 (OSRAM) |
| ES (1) | ES2773317T3 (OSRAM) |
| HU (1) | HUE047910T2 (OSRAM) |
| PL (1) | PL3065761T3 (OSRAM) |
| PT (1) | PT3065761T (OSRAM) |
| TW (1) | TWI729970B (OSRAM) |
| WO (1) | WO2015069668A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3252079B8 (en) | 2006-04-07 | 2020-09-09 | Aerpio Therapeutics LLC | Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof |
| AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint Pharmaceuticals, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
| US10568934B2 (en) | 2012-05-07 | 2020-02-25 | Allergan, Inc. | Method of treating AMD in patients refractory to anti-VEGF therapy |
| NZ770284A (en) | 2018-05-10 | 2025-11-28 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations |
| US10894824B2 (en) | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
| EP3980045A1 (en) * | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Recombinant fap binding proteins and their use |
| IL301762A (en) * | 2020-10-07 | 2023-05-01 | Line 6 Biotechnology Inc | Methods and materials for the treatment of eye diseases |
| WO2022074623A1 (en) | 2020-10-08 | 2022-04-14 | Notal Vision Ltd. | Oct guided therapy |
| CN114075290B (zh) * | 2022-01-20 | 2022-04-19 | 南京鼓楼医院 | Cd40靶向结合蛋白、其编码核酸以及用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4723140B2 (ja) | 1999-06-08 | 2011-07-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された薬物動態特性を有する改変キメラポリペプチド |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP1996937A4 (en) | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
| WO2008097497A2 (en) | 2007-02-02 | 2008-08-14 | Adnexus, A Bristol-Myers Squibb R & D Company | Vegf pathway blockade |
| DE602008005596D1 (de) | 2007-06-21 | 2011-04-28 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| RU2550258C2 (ru) | 2008-11-03 | 2015-05-10 | Молекьюлар Партнерс Аг | Связывающие белки, ингибирующие взаимодействия vegf-a рецептора |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| US10568934B2 (en) * | 2012-05-07 | 2020-02-25 | Allergan, Inc. | Method of treating AMD in patients refractory to anti-VEGF therapy |
-
2014
- 2014-11-04 CA CA2927012A patent/CA2927012A1/en not_active Abandoned
- 2014-11-04 KR KR1020167014741A patent/KR20160070164A/ko not_active Ceased
- 2014-11-04 US US14/532,397 patent/US20150126458A1/en not_active Abandoned
- 2014-11-04 WO PCT/US2014/063951 patent/WO2015069668A1/en not_active Ceased
- 2014-11-04 ES ES14802544T patent/ES2773317T3/es active Active
- 2014-11-04 PT PT148025448T patent/PT3065761T/pt unknown
- 2014-11-04 PL PL14802544T patent/PL3065761T3/pl unknown
- 2014-11-04 CN CN201480060463.5A patent/CN105960247A/zh active Pending
- 2014-11-04 HU HUE14802544A patent/HUE047910T2/hu unknown
- 2014-11-04 JP JP2016552455A patent/JP2016536369A/ja active Pending
- 2014-11-04 AU AU2014346921A patent/AU2014346921A1/en not_active Abandoned
- 2014-11-04 DK DK14802544.8T patent/DK3065761T3/da active
- 2014-11-04 EP EP19192065.1A patent/EP3628324A1/en not_active Withdrawn
- 2014-11-04 EP EP14802544.8A patent/EP3065761B1/en active Active
- 2014-11-05 TW TW103138456A patent/TWI729970B/zh not_active IP Right Cessation
-
2016
- 2016-08-05 US US15/230,244 patent/US20170157207A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,290 patent/US20210008158A1/en not_active Abandoned
- 2020-05-05 AU AU2020202968A patent/AU2020202968A1/en not_active Abandoned
- 2020-06-22 JP JP2020106978A patent/JP2020169191A/ja active Pending
-
2021
- 2021-10-13 US US17/500,315 patent/US20220175881A1/en not_active Abandoned
-
2022
- 2022-05-06 JP JP2022076645A patent/JP2022107628A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536369A5 (OSRAM) | ||
| JP6355032B2 (ja) | 新規組換え二機能性融合タンパク質、それらの調製および使用 | |
| JP2020169191A5 (OSRAM) | ||
| US20220096596A1 (en) | Method of treating amd in patients refractory to anti-vegf therapy | |
| JP2016516016A5 (OSRAM) | ||
| JP2015502336A5 (OSRAM) | ||
| JP2016514132A5 (OSRAM) | ||
| JP2015522576A5 (OSRAM) | ||
| JP2017538395A5 (OSRAM) | ||
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| JP2022107628A (ja) | 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 | |
| JP2019531259A5 (OSRAM) | ||
| JP2015096065A5 (OSRAM) | ||
| CN117467025B (zh) | 一种抗vegf和补体双功能融合蛋白及其应用 | |
| JP2017534645A5 (OSRAM) | ||
| JP2018530574A5 (OSRAM) | ||
| WO2016122996A1 (en) | Vegfa/ang2 compounds | |
| EP4584295A1 (en) | Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies | |
| JP2009519025A5 (OSRAM) | ||
| JP2018509423A5 (OSRAM) | ||
| CN113195532B (zh) | 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法 | |
| JP2009538916A5 (OSRAM) | ||
| JP2012529423A5 (OSRAM) | ||
| US20240279324A1 (en) | Multispecific antagonists | |
| JPWO2022050176A5 (OSRAM) |